Statement of Principles concerning narcolepsy (Balance of Probabilities) (No. 12 of 2022)

The central concept is the definition of narcolepsy in subsection 7(2): a chronic neurological disorder of sleep regulation and wakefulness characterised by disabling, excessive, and irresistible daytime sleepiness lasting for at least three months, with varying amounts of cataplexy, hypnagogic hallucinations, and sleep paralysis. The instrument includes both narcolepsy with cataplexy (type 1) and without cataplexy (type 2). However, it expressly excludes early‑onset narcolepsy and daytime sleepiness caused by another condition that disrupts sleep duration or quality, such as circadian rhythm disorders, insufficient sleep, or substance effects. The diagnosis must be established by appropriate clinical testing, including sleep studies, the multiple sleep latency test, and measurement of orexin levels in cerebrospinal fluid. This definition is narrower than the clinical spectrum of daytime sleepiness disorders and directly limits the scope of claims. The instrument also introduces the concept of “terminal event” in Schedule 1 - Dictionary to cover death from narcolepsy: pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function contributed to by the person’s narcolepsy. The core practical concept is the factor list in section 9. There are fifteen factors, divided into eight for clinical onset (subsections 9(1) to 9(7) plus 9(15)) and a parallel set for clinical worsening (subsections 9(8) to 9(15)). The factors include: concussion or moderate to severe traumatic brain injury within two years before onset (with a special rule for sustained unconsciousness); neurosurgical procedure involving hypothalamus, midbrain, or brainstem within two years; therapeutic radiation to the brain within three years; a neurological disease, neurodegenerative disease, or paraneoplastic neurological syndrome involving the hypothalamus, midbrain, or brainstem within two years; a benign or malignant neoplasm or non‑malignant space‑occupying lesion in those brain regions within two years; receipt of the adjuvanted influenza H1N1 vaccine PandemrixTM within two years; infection of the pharynx with Streptococcus pyogenes within three years; and inability to obtain appropriate clinical management for narcolepsy. Each factor is time‑limited and anatomically specific, reflecting the medical evidence accepted by the Authority. The concept of “clinical onset” versus “clinical worsening” is critical: worsening factors apply only to aggravation of a pre‑existing condition, and the onset factors cannot be used to claim a worsening. The factor “inability to obtain appropriate clinical management” applies to both onset and worsening and captures situations where a lack of proper treatment itself contributed to the development or deterioration of narcolepsy, though it imposes a high evidentiary bar. The instrument also includes a note listing examples of neurological diseases that can involve the relevant brain regions, such as cerebrovascular accident, multiple sclerosis, and Parkinson’s disease, but these are non‑exhaustive. The “relevant service” definition in Schedule 1 restricts the instrument’s operation to eligible war service (other than operational service), defence service (other than hazardous service and British nuclear test defence service) under the VEA, and peacetime service under the MRCA. This means that claims arising from operational service or hazardous service must be assessed under a different Statement of Principles using the reasonable hypothesis standard.

The instrument directly affects veterans and members of the Forces who claim that their narcolepsy or death from narcolepsy is related to their service. Specifically, it applies to two categories of claimants. First, those under the Veterans' Entitlements Act 1986 who render “eligible war service (other than operational service)” or “defence service (other than hazardous service and British nuclear test defence service)”. This excludes most combat veterans, who are covered by the reasonable hypothesis standard under section 120 of the VEA. Second, those under the Military Rehabilitation and Compensation Act 2004 who render “peacetime service”. The instrument does not apply to claims for operational service under the VEA or hazardous service or British nuclear test defence service, nor to members with warlike or non‑warlike service under the MRCA. In practice, this means the main affected populations are veterans of peacetime service, non‑operational deployments, and some defence service personnel. The instrument also indirectly affects decision‑makers within the Department of Veterans’ Affairs and the Military Rehabilitation and Compensation Commission, who are bound to apply these factors when determining liability. Medical practitioners preparing reports for claims are affected because the instrument requires specific evidence addressing each factor, such as the timing of traumatic brain injury or the precise anatomical involvement of a neurological disease. Legal representatives and advocates must understand the factor structure and the distinction between onset and worsening to frame claims correctly. The exclusion of early‑onset narcolepsy means that claimants who could demonstrate narcolepsy developing before a certain age (not defined in the instrument) will be denied regardless of the presence of service factors. Claimants with daytime sleepiness due to other conditions such as shift work or substance use are also excluded, even if the sleepiness is severe. The instrument’s reliance on orexin measurement and multiple sleep latency testing means that claimants who do not have access to such testing at the relevant time may face difficulty satisfying the definition. The instrument also affects the dependents of deceased veterans who die from a terminal event to which narcolepsy contributed, as those dependents must demonstrate that the deceased had narcolepsy meeting the defined criteria and that one of the factors applied. The instrument does not affect operational service claimants or those with hazardous service, who are governed by a separate instrument (the reasonable hypothesis version), but those claimants could still be guided by this instrument as part of the medical evidence.

The instrument imposes no duties on claimants directly; rather, it establishes a right for claimants to have their claim accepted if they can prove, on the balance of probabilities, that at least one factor in section 9 exists and that the factor is related to their relevant service. Once a factor is established, the decision‑maker is required to determine that the narcolepsy or death is connected with service, subject to the relationship to service requirement in section 10. This creates a rebuttable presumption in favour of the claimant when the factor is proven. The instrument also grants a right to have the claim considered under the correct standard of proof: claims under s120B VEA or s339 MRCA must use this instrument’s factors rather than the reasonable hypothesis standard. The primary duty lies with the Repatriation Medical Authority to base the instrument on sound medical‑scientific evidence, as stated in section 8. The Authority has performed that duty by selecting factors it considers more probable than not to be causally linked. Decision‑makers have a duty to apply the instrument as a binding legislative instrument; they cannot substitute their own opinion on causation if a factor is satisfied. Claimants have the right to rely on factor 15, inability to obtain appropriate clinical management, which is a more open‑ended factor compared to the others. However, it is not defined and puts the evidentiary burden on the claimant to show that inadequate management contributed to the onset or worsening of narcolepsy. The instrument also creates a right for a claimant to raise factors that refer to another injury or disease covered by a different Statement of Principles; in that case, section 11 directs that the factors of that other SoP apply as in force from time to time. This ensures that secondary causation pathways are recognised - for example, a traumatic brain injury that is itself accepted as service‑related can then be used as a factor for narcolepsy. Conversely, the instrument creates no right for claimants whose narcolepsy is early‑onset or caused by other sleep disruptions, as those are specifically excluded from the definition. Claimants also have no right to rely on factors outside the list unless the decision‑maker considers other medical evidence sufficient to establish a connection without the instrument’s assistance, which would be unusual given the instrument’s binding nature. The instrument does not create a right to clinical management; factor 15 only addresses the absence of appropriate management as a causal factor.

This instrument does not create penalties or criminal offences. It is a legislative instrument that sets the evidentiary standard for administrative decision‑making in veterans’ compensation claims. Enforcement is therefore indirect, through the claims review and appeal processes. If a decision‑maker fails to apply the instrument correctly, the claimant may seek merits review by the Veterans’ Review Board or the Administrative Appeals Tribunal, or judicial review in the Federal Court on grounds of jurisdictional error. The instrument itself does not provide a private right of action. The Repatriation Medical Authority is not subject to penalties for errors in the instrument; its decisions are made on the basis of the medical‑scientific evidence available and are subject only to the statutory framework of the VEA. Claimants who misrepresent facts to satisfy a factor could face penalties under the general law for making false statements in compensation claims, such as those in the Criminal Code or the VEA itself, but these are not mentioned in this instrument. The instrument’s repeal of the previous SoP No. 8 of 2014 means that any claim pending on the commencement date (31 January 2022) must be determined under the new instrument, unless transitional provisions in the VEA or MRCA require otherwise. Non‑compliance by a decision‑maker with the instrument’s factors would be an error of law, likely leading to the decision being set aside on review. The instrument is enforceable by the decision‑maker as a direction: once a factor is established, the decision‑maker must accept the connection. There is no discretion to reject a claim that satisfies a factor, provided the factor is related to service. The lack of penal provisions reflects the instrument’s nature as an evidentiary rule, not a regulatory code. However, the instrument has significant financial enforcement consequences: it either entitles a claimant to benefits (pension, medical treatment, compensation) or denies them. The effective “penalty” for not meeting a factor is denial of the claim. The instrument also ensures that claims are processed uniformly, reducing the risk of arbitrary decisions but also creating a rigid framework that may exclude meritorious claims falling outside the listed factors. The Repatriation Medical Authority is subject to the Legislative Instruments Act 2003 (now the Legislation Act 2003) regarding registration, tabling, and disallowance, but those are external enforcement mechanisms.

The instrument is made under the Veterans' Entitlements Act 1986, specifically subsection 196B(3), and must be read in the context of that Act and the Military Rehabilitation and Compensation Act 2004. It directly replaces the earlier Statement of Principles No. 8 of 2014 for narcolepsy, meaning any reference to the earlier instrument in decisions is superseded from 31 January 2022. The instrument interacts with section 120B of the VEA, which sets out the balance of probabilities standard for claims not involving operational service, and with section 339 of the MRCA, which sets the standard for peacetime service claims. For claims involving operational service under the VEA, a separate instrument made under subsection 196B(2) (reasonable hypothesis) applies; this instrument does not apply to those claims. However, the definition of narcolepsy and the factors may be used as evidence in operational service claims, but they are not binding. Section 11 of the instrument contains a crucial interaction provision: if a factor in section 9 refers to an injury or disease that is itself the subject of another Statement of Principles determined under s196B(3) (i.e., a balance of probabilities SoP), then the factors of that other SoP apply as in force from time to time. This means that, for example, if factor 1 requires a concussion or traumatic brain injury, the claimant may need to establish that the traumatic brain injury is itself related to service, using the relevant SoP for traumatic brain injury. This creates a cascading framework of SoPs that a claimant must navigate. The instrument also interacts with the general law of evidence and administrative law. It does not override the requirement for the claim to be related to service; section 10(1) stresses that the factor must be related to the relevant service rendered by the person. If a factor is satisfied but the factor itself is not related to service, the claim fails. The instrument does not interact with state or territory workers’ compensation laws, as it is exclusively federal veterans’ law. It also does not interact with the National Disability Insurance Scheme or social security laws, though a veteran may hold dual entitlements. The exclusion of early‑onset narcolepsy and daytime sleepiness from other causes means that claimants with those conditions may need to rely on other legislative schemes if service connection is not possible. The instrument’s dictionary defines relevant service in a way that excludes operational service under VEA and hazardous service under MRCA, reinforcing the interaction with the two separate statutory regimes. The instrument does not interact with the common law of tort; veterans’ compensation is a no‑fault scheme, so there is no right to sue the Commonwealth for negligently causing narcolepsy. However, if a third party is responsible (e.g., a vaccine manufacturer), the instrument does not affect a separate civil action. Finally, the instrument adopts ICD‑10‑AM code G47.4 for narcolepsy but clarifies that the meaning of narcolepsy for the instrument is the defined one, not necessarily how it is coded in medical records; a hospital coding alone is insufficient to establish the condition under the SoP.

The instrument is No. 12 of 2022, dated 24 December 2021, and commenced on 31 January 2022. It repeals the Statement of Principles concerning narcolepsy No. 8 of 2014 (registered as F2014L00025). There is no information in the source text about any amendments between 2014 and 2022, or any subsequent amendments to this 2022 instrument. The instrument has not been amended as at the date of publication. The previous instrument No. 8 of 2014 was made under both subsections 196B(3) and (8) of the VEA; the new instrument is made only under subsection 196B(3). Subsection 196B(8) relates to statements of principles for operational service (reasonable hypothesis), so the repeal of the 2014 instrument under both subsections suggests that the new instrument supersedes it for both standards, but the new instrument expressly states it is made under subsection 196B(3) only. This means the 2014 instrument may still apply for reasonable hypothesis claims (if not repealed) or a separate instrument has been made for that standard. The source text does not indicate that a reasonable hypothesis version was made concurrently; presumably a separate instrument was made. The only amendment history available is the repeal of the predecessor. There is no indication of any transitional provisions, so claims already in progress as at 31 January 2022 would generally be determined under the new instrument unless transitional rules in the VEA or MRCA preserve the old instrument. The instrument’s name includes “(Balance of Probabilities)” to distinguish it from the reasonable hypothesis version. The Chairperson who affixed the common seal is Professor Terence Campbell AM, serving as Chairperson of the Repatriation Medical Authority at that time. The instrument’s commencement date is 31 January 2022, almost five weeks after it was sealed on 24 December 2021, allowing time for publication and transition. There is no amendment history within this instrument itself; it is a standalone replacement. Future amendments could occur if new medical‑scientific evidence emerges, prompting the Authority to review and vary the factors. The Authority is required under section 196C of the VEA to review SoPs periodically, so amendment history is likely to continue.

The source text does not mention any litigation history. As a relatively recent instrument (commenced 2022), there is likely no reported case law specifically interpreting its provisions. The predecessor instrument No. 8 of 2014 would have been the subject of many Administrative Appeals Tribunal and Veterans’ Review Board decisions, but those are not cited. The instrument itself is administrative in nature, so litigation would typically involve a challenge to a decision applying, or failing to apply, the factors. Common grounds of review include: whether the decision‑maker correctly interpreted the definition of narcolepsy (e.g., whether the claimant satisfied the three‑month sleepiness requirement); whether the clinical onset or worsening occurred within the specified time periods; whether a condition such as a cerebrovascular accident truly involved the hypothalamus, midbrain, or brainstem; whether the vaccine Pandemrix was actually received; and whether the inability to obtain appropriate clinical management was proven. The instrument’s precise anatomical references (hypothalamus, midbrain, brainstem) have likely generated disputes over medical evidence. The exclusion of early‑onset narcolepsy has probably been litigated to determine the cutoff age, though the instrument does not define “early onset”. The requirement that narcolepsy must be “chronic” and symptoms present for at least three months is also likely to be contested. The factor for concussion or traumatic brain injury includes a special rule for sustained unconsciousness, which may require interpretation of what constitutes “sustained”. The instrument does not define “moderate to severe” traumatic brain injury, inviting reliance on clinical guidelines. The factor for infection with Streptococcus pyogenes within three years is narrow; it does not cover other infections. The instrument’s interaction with other SoPs through section 11 has likely led to litigation about whether the referenced injury or disease is itself subject to a SoP and whether that SoP has been satisfied. The instrument’s application only to “relevant service” as defined has been a source of jurisdictional disputes. Because the instrument is binding, any failure by a decision‑maker to consider a claimed factor is an error of law. The Administrative Appeals Tribunal often reviews decisions under these SoPs, and the Federal Court occasionally reviews questions of law. No specific cases are named in the source, but standard veterans’ law databases would contain numerous decisions applying the 2014 narcolepsy SoP and now this 2022 version.

Several provisions in the instrument create traps for the unwary. First, the definition of narcolepsy in subsection 7(2) is deceptively narrow. It requires symptoms lasting for at least three months and excludes early‑onset narcolepsy without defining “early onset”. Clinicians and claimants may not recognise that a diagnosis from a doctor does not automatically satisfy the SoP definition; the decision‑maker must confirm that the condition is not early onset. Second, the instrument excludes daytime sleepiness caused by another condition that disrupts sleep duration or quality, with examples including shift work and insufficient sleep. A claimant who also has sleep apnoea or works night shifts may be excluded even if they have true narcolepsy. Third, the time windows for each factor are strict and must be measured from the clinical onset or clinical worsening of narcolepsy. For traumatic brain injury, the instrument imposes two sub‑timeframes: within two years before onset, and in cases of sustained unconsciousness, within two years of regaining consciousness. This “regaining consciousness” trigger is easy to overlook and may cut off claims where the unconsciousness was prolonged but the onset of narcolepsy occurred shortly after injury. Fourth, the factor for the Pandemrix vaccine is specific to that brand; it does not cover other H1N1 vaccines used in Australia or abroad. A claimant who received a different brand cannot rely on factor 6 or 13. Fifth, the factor for Streptococcus pyogenes infection is limited to pharyngeal infection; a claimant with a strep infection elsewhere (e.g., skin) cannot rely on factor 7 or 14. Sixth, the “inability to obtain appropriate clinical management” factor (factor 15) looks generous but is hard to prove. The instrument does not define “appropriate clinical management” or “inability”. It likely requires evidence that clinically recommended treatment was available and reasonably accessible but not provided, and that this lack contributed to onset or worsening. It does not cover situations where management was inadequate due to poor medical advice. Seventh, the instrument distinguishes between clinical onset and clinical worsening factors. Claimants with pre‑existing narcolepsy seeking to establish aggravation must satisfy a worsening factor (subsections 9(8) to 9(14) plus 9(15)). They cannot use the onset factors even if the condition was asymptomatic before service; the condition must have been suffered or contracted before or during service but not arisen out of it. Eighth, the definition of “relevant service” excludes operational service under VEA and hazardous service under MRCA. A claimant with operational service may mistakenly bring a claim under this instrument and be denied, when they should have used the reasonable hypothesis standard. Ninth, the instrument uses the ICD‑10‑AM code but clarifies that the code is not determinative; the definition in subsection 7(2) controls. A medical certificate quoting the code may be insufficient if it does not address the exclusions. Tenth, the dictionary definition of “terminal event” includes only five specific causes; a death from narcolepsy that results from another cause (e.g., a motor vehicle accident caused by sleepiness) is not covered unless it leads to one of those events. Finally, the note under subsection 7(2) lists examples of other conditions that can cause daytime sleepiness but does not make them presumptive exclusions; however, decision‑makers may interpret the provision broadly, requiring the claimant to exclude these possibilities.

Compliance with this instrument is relevant primarily for two audiences: claimants and their representatives, who must structure their claim to satisfy at least one factor; and decision‑makers, who must apply the instrument accurately. For a claimant, the first step is to confirm that the claim falls within the scope of the instrument: the narcolepsy must meet the defined criteria (chronic, at least three months, not early onset, not caused by other sleep disruption). A comprehensive diagnosis including multiple sleep latency test results and, where possible, cerebrospinal fluid orexin measurement should be obtained. The claim should then focus on identifying any potential factor from section 9 that matches the claimant’s medical history. The timing of the factor relative to clinical onset or worsening is critical; medical records must clearly document the date of first onset of excessive daytime sleepiness or the date of a significant worsening. For concussion or traumatic brain injury, the claimant must establish that the injury was at least moderate to severe, and the narcolepsy must have developed within two years; if unconsciousness was sustained, the clock starts from regaining consciousness. For neurological diseases or neoplasms, imaging or biopsy evidence must prove involvement of the hypothalamus, midbrain, or brainstem. Generic involvement of the brain is insufficient. For the Pandemrix vaccine, the claimant must show receipt of that specific brand. For Streptococcus pyogenes infection, a throat swab or serology confirming the infection must be within three years. For inability to obtain appropriate clinical management, the claimant must demonstrate that appropriate management existed and was reasonably available but not provided, and that this directly contributed to onset or worsening. If the factor involves another injury or disease (e.g., traumatic brain injury), the claimant must also satisfy the relevant SoP for that condition under section 11, meaning the claim may become multi‑layered. The claimant must also prove that the factor is related to their relevant service as defined in the dictionary. This may require establishing that the traumatic brain injury occurred during training, the vaccine was given as part of a military inoculation program, or the neurosurgery was performed in a military hospital. For decision‑makers, compliance requires a careful analysis of the evidence against each factor, using the exact language of the instrument. If a factor is established and related to service, the decision‑maker must accept the connection; there is no discretion to deny on other grounds. The decision‑maker must also apply the correct standard of proof (balance of probabilities) and ensure that the claim is within the scope of the instrument (i.e., not operational or hazardous service). The decision‑maker should document which factor is found to exist and how it is related to service, or explain why none of the factors are met. Claimants who do not satisfy any factor may still argue that the evidence taken as a whole establishes a connection without relying on the instrument, but given the instrument’s binding nature, that route is practically difficult. Ongoing compliance involves keeping the instrument under review as medical evidence evolves; the Repatriation Medical Authority may amend the instrument, and the current version should always be cited. Practitioners advising claimants should check that the claim is not barred by the exclusion of early‑onset narcolepsy and that the diagnosis is consistent with the SoP definition. A pre‑emptive approach is to gather all relevant medical records well before the claim is lodged, paying particular attention to dates and the specific anatomical regions involved.